Pharma BD Deal Intelligence
Actiq became a ~$500M blockbuster for Cephalon, validating the $444M Anesta acquisition, though off-label marketing led to a $425M federal fraud settlement and generics erased the franchise by 2006. A mixed win: commercial success tainted by legal fallout and a short patent runway.
Actiq became a ~$500M blockbuster for Cephalon but its off-label marketing triggered a $425M federal fraud settlement, tainting the deal's legacy before generics arrived in 2006.
Full analysis, sources & comparables →Cephalon's $444M all-stock acquisition of Anesta gave it Actiq for breakthrough cancer pain plus a 60-person oncology sales force; CEO Frank Baldino called it…
Anesta shareholders approved the merger 10 October 2000; the combined company will focus on Provigil, Actiq and Gabitril, with Salt Lake City staffing…
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Cephalon Inc. acquired Anesta Corp. in an all-stock merger valued at approximately $444 million. The transaction gave Cephalon the marketed product Actiq (oral transmucosal fentanyl citrate) for breakthrough cancer pain, together with an approximately 60-person oncology sales force that broadened Cephalon's commercial reach beyond its CNS franchise (Provigil, Gabitril). Anesta shareholders approved the merger on October 10, 2000.
Actiq became a ~$500M blockbuster for Cephalon but its off-label marketing triggered a $425M federal fraud settlement, tainting the deal's legacy before generics arrived in 2006.
Assessment window: 15yr post-close.
$55M Actiq US sales projection 2001 (analyst estimate)
Breakthrough cancer pain is a transient flare of severe pain that breaks through scheduled around-the-clock opioid therapy in cancer patients. It demands rapid-onset rescue analgesia matched to the minutes-long pain peak, which standard oral opioids cannot achieve. NOTE: this deal_id appears to be a duplicate of the Cephalon-Anesta acquisition originally announced 2000-07 and closed 2000-10.
This record reflects the same Cephalon-Anesta transaction announced July 17, 2000 and closed October 10, 2000, with the 2001-04-30 date possibly representing a post-close integration milestone or filing date. Actiq (oral transmucosal fentanyl citrate) remained the only FDA-approved rapid-onset fentanyl for breakthrough cancer pain at this time, having been launched March 1999. The standard of care otherwise consisted of immediate-release oral morphine, oxycodone, and hydromorphone — all with 30-45 minute onset that did not match breakthrough pain kinetics. The all-stock $444M deal gave Cephalon a 60-person oncology sales force, complementing Provigil (modafinil) for narcolepsy and Gabitril (tiagabine) for epilepsy. Analyst Peter Ginsberg of US Bancorp Piper Jaffray rated Cephalon a 'strong buy'. The acquisition seeded Cephalon's later Fentora buccal tablet lifecycle play. Subsequent entrants (Onsolis, Abstral, Lazanda, Subsys) and REMS class labeling later constrained category growth, but at the time Actiq's first-mover position was unmatched. Recommend deduplicating this record against deal_id 51ce5b5eb90146949e14f18eceeeac76.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Anesta Corp. (this deal) | 2001 | $444M | 65 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2001 deals · Cephalon Inc. deals